Costs of Failure in Product Quality - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Costs of Failure in Product Quality
The authors detail the possible consequences of noncompliance and a lack of quality control.


Pharmaceutical Technology
Volume 36, Issue 4, pp. 110-118

References

1. "Drug Makers Catch FDA's Drift, Look to Reduce Variability," The Gold Sheet, 45, (1), 2011.

2. Jeffrey Macher, "A Practical Approach to Effective Lifestyle Implementation of Systems and Processes for Pharmaceutical Manufacturing," Business Case for Quality, Pharmaceutical Quality Systems (ICH Q10) Conference, Arlington, VA, Oct 46, 2011 and Brussels, Belgium, Nov. 1416, 2011.

3. PQRIFDA Workshop on Process Drift: Detection, Measurement, and Control in the Manufacture of Pharmaceuticals (Bethesda, MD, Dec. 13, 2010.

4. Margaret M. Szymczak et al., Pharm. Tech., 35 (10) 70-74 2011.

5. FDA, The Small Biz Buzz, CDER Small Business Update Thursday December 22, 2011; "Ben Venue LaboratoriesVoluntary Shutdown;" FDA Recalls, Updated Jan. 12, 2012.

6. FDA, Subject Drug Information UpdateFDA, Justice Department Take Action Against McNeil-PPC Inc., Mar. 10, 2011.

7. Expert Briefings, Dec. 22, 2011.

8. FDA, Press Release, "Department of Justice Files Consent Decree of Permanent Injunction Against Ranbaxy," Jan. 25, 2012.

9. Novartis Consumer Health Press Release, Jan. 12, 2012, issues voluntary Nationwide Recall of Certain Over-the-Counter Products.

10. Citations, Federal Food Drug and Cosmetic Act (21 U.S.C. 331337): Prohibited Acts and Penalties Sections 301-307.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here